DGNews
Treatment with anti-vascular endothelial growth factor receptors (VEGFs) to control oedema in age-related macular degeneration followed by maintenance therapy with pegaptanib enables patients to achieve long-term vision gains, according to research presented here at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting.